152 related articles for article (PubMed ID: 37033671)
1. Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension (NDLS) versus Conventional Docetaxel as Neoadjuvant and Adjuvant Therapy for Primary Operable Breast Cancer.
Badiginchala R; Dattatreya PS; Suresh AVS; Nirni SS; Andra VV; Bunger D; Chaturvedi A
Onco Targets Ther; 2023; 16():215-225. PubMed ID: 37033671
[TBL] [Abstract][Full Text] [Related]
2. Nanosomal Docetaxel Lipid Suspension-Based Chemotherapy in Breast Cancer: Results from a Multicenter Retrospective Study.
Subramanian S; Prasanna R; Biswas G; Das Majumdar SK; Joshi N; Bunger D; Khan MA; Ahmad I
Breast Cancer (Dove Med Press); 2020; 12():77-85. PubMed ID: 32547188
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension-Based Chemotherapy in Sarcoma: A Multicenter, Retrospective Study.
Narayanan P; Dattatreya PS; Prasanna R; Subramanian S; Jain K; Somanath NS; Joshi N; Bunger D; Khan MA; Chaturvedi A; Ahmad I
Sarcoma; 2019; 2019():3158590. PubMed ID: 31827370
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of nanosomal docetaxel lipid suspension based chemotherapy in gastric and gastroesophageal junction adenocarcinoma.
Subramanian S; Majumdar SKD; Biswas G; Joshi N; Bunger D; Khan MA; Ahmad I
Mol Clin Oncol; 2020 Sep; 13(3):14. PubMed ID: 32754328
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of nanosomal docetaxel lipid suspension-based chemotherapy in squamous cell carcinoma of the head and neck: A multicenter retrospective study.
Kumar Das Majumdar S; Subramanian S; Biswas G; Joshi N; Khan MA; Ahmad I
Oncol Lett; 2020 Dec; 20(6):344. PubMed ID: 33123255
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of nanosomal docetaxel lipid suspension based chemotherapy in metastatic ovarian carcinoma: A retrospective study.
Subramanian S; Samar A; Joshi N; Sejpal J; Khan MA; Ahmad I
Mol Clin Oncol; 2021 Aug; 15(2):162. PubMed ID: 34194740
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic efficacy of a novel nanosomal docetaxel lipid suspension compared with taxotere in locally advanced or metastatic breast cancer patients.
Ahmad A; Sheikh S; Taran R; Srivastav SP; Prasad K; Rajappa SJ; Kumar V; Gopichand M; Paithankar M; Sharma M; Rane RC; Ahmad I
Clin Breast Cancer; 2014 Jun; 14(3):177-81. PubMed ID: 24287370
[TBL] [Abstract][Full Text] [Related]
8. Nanosomal Docetaxel Lipid Suspension: A Guide to Its Use in Cancer.
McKeage K
Clin Drug Investig; 2017 Apr; 37(4):405-410. PubMed ID: 28255844
[TBL] [Abstract][Full Text] [Related]
9. Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trial.
Mackey JR; Pieńkowski T; Crown J; Sadeghi S; Martin M; Chan A; Saleh M; Sehdev S; Provencher L; Semiglazov V; Press MF; Sauter G; Lindsay M; Houé V; Buyse M; Drevot P; Hitier S; Bensfia S; Eiermann W
Ann Oncol; 2016 Jun; 27(6):1041-1047. PubMed ID: 26940688
[TBL] [Abstract][Full Text] [Related]
10. Dose-dense biweekly doxorubicin/docetaxel versus sequential neoadjuvant chemotherapy with doxorubicin/cyclophosphamide/docetaxel in operable breast cancer: second interim analysis.
Jackisch C; von Minckwitz G; Eidtmann H; Costa SD; Raab G; Blohmer JU; Schütte M; Gerber B; Merkle E; Gademann G; Lampe D; Hilfrich J; Tulusan AH; Caputo A; Kaufmann M
Clin Breast Cancer; 2002 Oct; 3(4):276-80. PubMed ID: 12425756
[TBL] [Abstract][Full Text] [Related]
11. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27.
Bear HD; Anderson S; Brown A; Smith R; Mamounas EP; Fisher B; Margolese R; Theoret H; Soran A; Wickerham DL; Wolmark N;
J Clin Oncol; 2003 Nov; 21(22):4165-74. PubMed ID: 14559892
[TBL] [Abstract][Full Text] [Related]
12. A randomized phase II trial of doxorubicin plus pemetrexed followed by docetaxel versus doxorubicin plus cyclophosphamide followed by docetaxel as neoadjuvant treatment of early breast cancer.
Schneeweiss A; Marmé F; Ruiz A; Manikhas AG; Bottini A; Wolf M; Sinn HP; Mansouri K; Kennedy L; Bauknecht T
Ann Oncol; 2011 Mar; 22(3):609-617. PubMed ID: 20732932
[TBL] [Abstract][Full Text] [Related]
13. Biweekly DoceAqualip in mCRPC patients beyond 20 cycles: A case series.
Tiwari S; Bisaria A; Kaur H; Joshi N; Sejpal J; Khan MA
J Oncol Pharm Pract; 2021 Dec; 27(8):2030-2034. PubMed ID: 33853469
[TBL] [Abstract][Full Text] [Related]
14. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27.
Bear HD; Anderson S; Smith RE; Geyer CE; Mamounas EP; Fisher B; Brown AM; Robidoux A; Margolese R; Kahlenberg MS; Paik S; Soran A; Wickerham DL; Wolmark N
J Clin Oncol; 2006 May; 24(13):2019-27. PubMed ID: 16606972
[TBL] [Abstract][Full Text] [Related]
15. Treatment with nanosomal paclitaxel lipid suspension
Satheesh CT; Taran R; Singh JK; Shrivastav SP; Vithalani NK; Mukherjee KK; Nagarkar RV; Maksud T; Mehta AO; Srinivasan K; Vikranth M; Sonawane SR; Ahmad A; Sheikh S; Ali SM; Patel R; Paithankar M; Patel L; Rajani A; Bunger D; Chaturvedi A; Ahmad I
Ther Adv Med Oncol; 2024; 16():17588359241236442. PubMed ID: 38680290
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.
Hurvitz SA; Martin M; Symmans WF; Jung KH; Huang CS; Thompson AM; Harbeck N; Valero V; Stroyakovskiy D; Wildiers H; Campone M; Boileau JF; Beckmann MW; Afenjar K; Fresco R; Helms HJ; Xu J; Lin YG; Sparano J; Slamon D
Lancet Oncol; 2018 Jan; 19(1):115-126. PubMed ID: 29175149
[TBL] [Abstract][Full Text] [Related]
17. Comparison of an AC-taxane versus AC-free regimen and paclitaxel versus docetaxel in patients with lymph node-positive breast cancer: Final results of the National Surgical Adjuvant Study of Breast Cancer 02 trial, a randomized comparative phase 3 study.
Watanabe T; Kuranami M; Inoue K; Masuda N; Aogi K; Ohno S; Iwata H; Mukai H; Uemura Y; Ohashi Y
Cancer; 2017 Mar; 123(5):759-768. PubMed ID: 28081304
[TBL] [Abstract][Full Text] [Related]
18. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial.
Gianni L; Pienkowski T; Im YH; Tseng LM; Liu MC; Lluch A; Starosławska E; de la Haba-Rodriguez J; Im SA; Pedrini JL; Poirier B; Morandi P; Semiglazov V; Srimuninnimit V; Bianchi GV; Magazzù D; McNally V; Douthwaite H; Ross G; Valagussa P
Lancet Oncol; 2016 Jun; 17(6):791-800. PubMed ID: 27179402
[TBL] [Abstract][Full Text] [Related]
19. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27.
Rastogi P; Anderson SJ; Bear HD; Geyer CE; Kahlenberg MS; Robidoux A; Margolese RG; Hoehn JL; Vogel VG; Dakhil SR; Tamkus D; King KM; Pajon ER; Wright MJ; Robert J; Paik S; Mamounas EP; Wolmark N
J Clin Oncol; 2008 Feb; 26(5):778-85. PubMed ID: 18258986
[TBL] [Abstract][Full Text] [Related]
20. Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial.
Swain SM; Tang G; Geyer CE; Rastogi P; Atkins JN; Donnellan PP; Fehrenbacher L; Azar CA; Robidoux A; Polikoff JA; Brufsky AM; Biggs DD; Levine EA; Zapas JL; Provencher L; Northfelt DW; Paik S; Costantino JP; Mamounas EP; Wolmark N
J Clin Oncol; 2013 Sep; 31(26):3197-204. PubMed ID: 23940225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
